Jefferies Starts Pieris Pharmaceuticals (PIRS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Evercore ISI Starts Pieris Pharmaceuticals (PIRS) at Outperform
March 19, 2018 8:08 AM EDTEvercore ISI initiates coverage on Pieris Pharmaceuticals (NASDAQ: PIRS) with an Outperform rating and a price target of $13.00.
Analyst Umer Raffat and Akash Tewari note while the platform and the preclinical pipeline, they focused specifically on the two key programs:
1.... More



